Drugs / HeFi-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00048880 | Nov 2002 → Jul 2008 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003741 | Feb 1999 → Dec 2007 | lymphoma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HeFi-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00048880 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody HeFi-1” NCT00003741 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody HeFi-1 IV over 30 minutes 3 times a week for 2 weeks.” NCT00003741 ↗ |
| Target | TNFRSF8 | “Tumor necrosis factor receptor superfamily member 8 binding agent” CHEMBL2109255 ↗ |